For biopharmaceutical companies that rely upon volunteers to participate in clinical research on potential new medicines, protecting privacy has always been a priority. Striking the appropriate balance between sharing data to drive medical discoveries and keeping personal health information from being disclosed is critical. According to recent articles in The Wall Street Journal and New [...]
Analyzing data related to first-year effects from all five study years (2003–2007), the study team found that enrollees who switched to consumer-directed plans spent 21 percent less on health care in their first year; furthermore, in contrast with the HIE’s results, approximately one-third of the savings resulted from lower spending per episode of care (Figure [...]
: Business Ethics and Leadership Home Beyond Compliance Ethics Codes Workplace Culture Case Studies Decision Making Insights Business Ethics Career Development Leadership Management Quotes , Observations Resources Donate QUOTES OBSERVATIONS : Notes for the Boss by Michael Josephson on January 28, 2013 Share : this Share Email Facebook Twitter Google 1 Print Cancel reply Leave a Comment Name E-mail Website Notify me of follow-up comments by . email Notify me of new posts by . email Previous post : Michael Josephson Named One of the Top Thought Leaders in Trustworthy Business Behavior Search Subscribe by email Guest bloggers welcome Read our guidelines Center for Business Ethics Business Consulting and Risk Management Customized Programs and Training Keynote Speeches and Presentations
We may be on “the verge of a renaissance in pharmaceutical R&D,” John Lechleiter, PhD, chairman of PhRMA and chairman, president and CEO of Eli Lilly and Company, declares in a great opinion piece posted today on Forbes’ website. Dr. Lechleiter makes this eloquent assertion as he describes the findings of the recent report on [...]
Many of The Catalyst posts this month have discussed different aspects of innovation, and this week, we focused on one of the most important elements: research and development. Innovation is the catalyst for researching and developing lifesaving new treatments that coupled with the right partnerships and idea sharing opportunities is key to ensuring long-term success. [...]
While the “Innovations and Inaugurations” series came to an end last week, we remain focused on the importance of collaboration between public and private partners to help advance innovation and the critical role that biopharmaceutical research companies play in improving health care for patients battling disease. In a guest blog post from Astellas, Catalyst readers [...]
Rotary International is leading a global fight to eradicate polio – and an end to polio may be within sight. To learn more about the fantastic work Rotary is doing around the globe, check-out its End Polio Now website. This work is extremely important as well as successful. In recognition of its value, PhRMA was excited [...]
Last week we released a new report by Analysis Group examining innovation in the biopharmaceutical pipeline. The report looked at the pipeline from several angles and presented many interesting findings – even some that were surprising. The pipeline is remarkably robust. There are more than 5,000 drugs in development and of those about 70% have [...]
Last week, the National Institutes of Health announced its support of four new studies aimed at finding new treatments for Alzheimer’s disease. The research projects, which are being administered under the Alzheimer’s Disease Cooperative Study (ADCS), reflect the breadth of emerging ideas and the range of stakeholders within the biopharmaceutical ecosystem (government, private companies, academia) [...]